Skip to main content
Profile picture for Hani El-Gabalawy, MD, FRCPC

Hani El-Gabalawy, MD, FRCPC

Dr. Hani El-Gabalawy is a Professor of Medicine and Immunology, senior clinician-scientist, Endowed Rheumatology Research Chair at the University of Manitoba, and the former Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute for Musculoskeletal Health and Arthritis.

Dr. El-Gabalawy received his pre-medical and medical studies degrees at the Faculties of Science and Medicine at the University of Calgary and completed his Internal Medicine training and Rheumatology Fellowship at McGill University.   From 1997-2000, he was a visiting scientist at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in Bethesda, Maryland.  In 2000, he returned to the U of Manitoba where he continued his research work in the area of pathogenesis and prognosis of early inflammatory arthritis. Dr El-Gabalawy has established a unique cohort of at-risk First Nations family members of RA patients who are being followed longitudinally for the earliest evidence of RA onset for which he has received uninterrupted funding from CIHR since 2005. His current research interests center around the mechanisms involved in the transition from benign to pathogenic autoimmunity and the initiation of synovial inflammation.

Articles By Hani El-Gabalawy, MD, FRCPC

question mark

Why aren’t we preventing RA yet?

Ever since the seminal studies demonstrating a prolonged preclinical period for seropositive RA, which have been replicated in multiple cohorts around the world using both retrospective and prospective study designs, the rheumatology community has been tantalized by the prospect of preventing the onset of inflammatory joint disease in seropositive individuals exhibiting no clinically detectable synovitis. So why can’t we prevent RA yet?

Read Article
×